The Korean Journal of Clinical Laboratory Science : eISSN 2288-1662 / pISSN 1738-3544

Table. 2.

Table. 2.

Summary of studies on clinical manifestations of COVID-19 in Korea

KCDC (N=28) Park PG (N=309) Dawei Wang (N=138)
Characteristics of the study and study area First patient from the Korean cohort study: Republic of Korea Cohort study about admission day to hospital: Community treatment center, Republic of Korea Clinical characteristics of hospitalized patients: Wuhan, China
Study period 19 Jan∼17 Feb, 2020 2 Mar∼18 Mar, 2020 1 Jan∼28 Jan, 2020
Sex, male (%) 15 (53.6%) 124 (40.1%) 75 (54.3%)
Age, median (range) 40 years (range: 20∼73 years) 31 years (range:7∼77 years) 56 years (range: 42∼68)
Symptom on admission day
Fever 7 (25%) (>37.5°C) NA 136 (98.6%)
Cough 8 (28.6%) 50 (16.2%) 82 (59.4%)
Sore throat 8 (28.6%) 24 (7.8%) NA
Rhinorrhea 2 (7.1%) 49 (15.9%) NA
Dyspnoea 1 (3.6%) NA 43 (31.2%)
Chest pain NA 12 (3.9%) NA
Headache 7 (25%) NA 9 (6.5%)
Myalgia 7 (25%) NA 48 (34.8%)
Sputum 6 (21.4%) 39 (12.7%) 37 (26.8%)
Diarrhea 3 (10.7%) NA 14 (10.1%)
Fatigue 3 (10.7%) NA 96 (69.6%)
Asymptomatic 2 (7.1%) 176 (57.1%) N/A
Laboratory findings Lymphopenia 7 (25.0%) C-reactive protein level (≥10 mg/L)↑ 7 (25.0%) Infiltration in chest X-ray 13 (46.4%) Infiltration in CT 16 (88.9%) Pneumonia 2 (0.7%) Lymphocyte↓ 0.8 (0.6∼1.1) (x109/L) Procalcitonin↑ 49 ng/mL (35.5%)

Abbreviations: KCDC, Korea Centers for Disease Prevention and Control; N/A, Not available.

Korean J Clin Lab Sci 2020;52:284-95 https://doi.org/10.15324/kjcls.2020.52.3.284
© 2020 Korean J Clin Lab Sci